2020-10-29 OMA Agenda - Board of Trustees

and ameliorate comorbidities and amplify adherence to behavior changes in individuals with a BMI ≥30 kg/m 2 or in individuals with a BMI of ≥27 kg/m 2 and at least one associated comorbid medical condition such as hypertension, dyslipidemia, T2DM, and obstructive sleep apnea. Assessment of efficacy and safety at least monthly for the first 3 months, then at least every 3 months in all patients prescribed weight loss medications. If a patient’s response to a weight loss medication is deemed effective (weight loss 5% of body weight at 3 mo) and safe, we recommend that the medication be continued. If deemed ineffective (weight loss 5% at 3 mo) or if there are safety or tolerability issues at any time, we recommend that the medication be discontinued and alternative medications or referral for alternative treatment approaches be considered. If medication for chronic obesity management is prescribed as adjunctive therapy to comprehensive lifestyle intervention, we suggest initiating therapy with dose escalation based on efficacy and tolerability to the recommended dose and not exceeding the upper approved dose boundaries. This guideline also addresses medication prescribing for patients with obesity to treat hypertension, type 2 diabetes, cardiovascular disease, depression as well as prescribing of antipsychotic, antiepileptic, contraception, nonsteroidal anti-inflammatory, antirheumatic, and antihistamine medications.

27